CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 06/22/22

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M....

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP ...

Cyclacel Pharmaceuticals press release (NASDAQ:CYCC): Q1 GAAP EPS of -$0.42 beats by $0.27. As of March 31, 2022, cash and cash equivalents totaled $29.6 million, compared to $36.6 million as of December 31, 2021. The Company estimates that its available cash will fund currently planned ...

- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publicat...

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on...

BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Compan...

3 Penny Stocks to Watch Ahead of the Stock Market Open Today After a less than stellar day of trading penny stocks on April 11th, investors have high hopes for today. In the past few weeks, anyone who has traded either penny stocks or blue chips is no stranger to volatility. [...

Shares of biopharmaceutical company Cyclacel Pharmaceuticals (NASDAQ:CYCC) have added 13.2% in premarket trading on Tuesday after announcing publication of preclinical data confirming that its CDK2/9 inhibitor fadraciclib suppresses the protein MCL1 and synergizes with oral therapy venetoclax...

Biodesix (BDSX) +53%. Actinium Pharmaceuticals ATNM +44% on agreement with Immedica Pharma for conditioning agent. BioCardia BCDA +34% after FDA nod to begin trial of BCDA-04 in COVID patients. Aeglea BioTherapeutics AGLE +19% on filing seeking FDA approval of pe...

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceu...